Close menu




October 26th, 2020 | 11:28 CET

Adva Optical Networking, Desert Gold, Va-Q-tec: Does it start now?

  • Investments
Photo credits: pixabay.com

"Good numbers, bad numbers." What does that even mean? Often it is the figures or news the Companies publish, only the deviation from expected values or developments. Ultimately, the decisive factor is whether or not a company passes the bar. But the devil is in the details. Here are three companies that have benefited from positive figures or news or where a good news flow is only a matter of time. Who offers the best opportunities?

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: CA25039N4084 , DE0005103006 , DE0006636681

Table of contents:


    ADVA OPTICAL NETWORKING SE - are there any more positive surprises in store?

    Adva Optical Networking is a leading provider of open network solutions for the delivery of cloud and mobile services. Last Wednesday the Company published its figures for the third quarter. With a minimal increase in sales to EUR 146.7 million, pro forma operating earnings rose by 49.5% year-on-year to EUR 7.4 million. Adva thus continued the strong profitability achieved in the second quarter. According to the Company's statement, both substantial cost reductions and new customer business led to the progress made.

    Adva also updated its outlook for the year as a whole. The group now expects to post sales of between EUR 565 and 580 million in 2020. The margin based on pro forma operating profit is expected to be 5% to 6%. In Q3, an increase from 5.1% to 7.4%, was achieved. The old forecast for the full year, which was for sales of more than EUR 580 million and a margin target of more than 5%, was capped in April.

    All in all, Adva delivered excellent figures. The increase in margins is impressive. Looking at the margin of 7.4% in Q3, the target of 5% to 6% for the year as a whole already seems modest. Adva should be able to leap over this benchmark and once again surprise investors positively.

    DESERT GOLD VENTURES INC - good entry point after price correction

    The gold explorer Desert Gold Ventures focuses entirely on the West African country of Mali. The Company is exploring two promising projects SMSZ and Djimbala in the south. Several big names such as Barrick, B2Gold, Endeavour, and Resolute have also committed themselves to the activity in Mali. Already in August, Desert Gold was able to carry out a capital increase of CAD 6.8 million. In late September, the TSX-V-listed Company released positive drill results.

    After a brilliant performance this year, which peaked in the summer at CAD 0.32, the share price dropped significantly to CAD 0.16. The market capitalization is currently CAD 21 million.

    Given the intact fundamental environment for gold and the excellent project quality, there is a perfect opportunity for investors to become involved after the significant price setback. Good news is only a matter of time.

    VA-Q-TEC AG - Profiteer of temperature-sensitive corona vaccines

    Va-Q-tec AG is a supplier of vacuum insulation panels and thermal energy storage components, as well as thermo boxes and containers for the transport of temperature-sensitive goods. The Würzburg-based Company's applications are essential for customers in the pharmaceutical sector, among others, because medicines should not be exposed to high-temperature fluctuations during transport to ensure the effectiveness of the ingredients.

    The Systems division (sale of thermoboxes) grew dynamically by 77% year-on-year in the first half of the current fiscal year. It contributed 10.5 million to total sales of EUR 35.7 million Euro (previous year: EUR 31.3 million). The Company will publish the reporting data for the third quarter on November 12.

    The following is the basis of the Goldylocks scenario for the share: If temperature-sensitive Corona vaccines were to become available soon, the Würzburg-based Company would undoubtedly benefit from this through its services. Currently, a good 2/3 of the customers are already from the pharmaceutical industry. This share would then increase significantly. With prices of around EUR 24.00, the share has already priced in quite a bit, but not everything.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Mario Hose on January 18th, 2022 | 16:37 CET

    Buy Long-Covid Stock Now? BioNTech, Cardiol, Mainz Biomed

    • Investments

    The second trading day this week is characterized by a weak start to trading. In the first two hours, the German indices have clearly lost ground. The leading index DAX is currently trading at 15,776 points, down around 1.05% on the previous day. The MDAX last traded at 34,156 points (-1.38%), TecDAX at 3,498 points (-1.77%) and SDAX at 15,658 points with 1.65% in the red. In the focus of market participants today are repeatedly the shares of vaccine manufacturers, but the trend is now also to the next phase of the Corona situation, the treatment of Long-Covid.

    Read

    Commented by Mario Hose on January 17th, 2022 | 15:57 CET

    Which stocks should investors buy? BioNTech, Desert Gold, Unilever in focus

    • Investments

    The start of the week in Germany has been mixed. At 15,937 points, the German benchmark index DAX is almost unchanged from the close of trading last Friday. No impulses are expected from the U.S. today, as the stock market there remains closed for the holiday. The MDAX last traded at 34,667 points (+0.24%), TecDAX at 3,563 points (+0.53%) and SDAX at 15,872 points with 0.07% in the red. Detached from the indices, investors have special opportunities today in individual stocks.

    Read

    Commented by Armin Schulz on January 14th, 2022 | 11:06 CET

    Lufthansa, wallstreet:online, Block - Shares with catch-up potential

    • Investments

    The nervousness was palpable as the US indices fell for five days in a row. Reasons for consolidation are quickly found - the Omicron variant, inflation and the fear of rising interest rates provide uncertainty for the bulls. Especially the big tech companies would suffer from an interest rate hike, and many tech stocks were already punished and investors preferred to invest in value stocks. If the interest rate hike comes, there will likely be further markdowns in the tech sector. Today, we look at three companies that we believe could be on the verge of a turnaround.

    Read